[1] 郝婷婷,马晓鹏,刘文娜,等.Logistic回归分析乙肝肝硬化并发原发性肝癌的危险因素.医学理论与实践,2015,28:2433-2435. [2] 占春玲.乙肝肝硬化并发原发性肝癌危险因素的Logistic回归分析.医学临床研究,20016,33:1697-1701. [3] 张志和,姜凤仙,何颖.肝炎后肝硬化并发肝癌的危险因素分析.海南医学,2014,25:24-25. [4] 林小钦,刘邦,李东良,等.肝炎后肝硬化并发肝癌的相关危险因素探讨.当代医学,2016,22:37-38. [5] 李想.乙肝肝硬化并发原发性肝癌的危险因素分析.临床医学,2015,35:48-50. [6] 闫宏,闫囡.乙肝肝硬化并发原发性肝癌的危险因素分析.齐齐哈尔医学院学报,2015,36:2911-2912. [7] Zhang H, Wu LY, Zhang S,et al.Anti-hepatitis B virus X protein in sera is one of the markers of development of liver cirrhosis and liver cancer mediated by HBV.J Biomed Biotechnol,2009,2009:289068. [8] 王晓丽.乙肝肝硬化并发原发性肝癌相关危险因素分析. 中国实用医药,2015,10:38-40. [9] 薛伟红,王友春,韩宏锋,等. 乙型肝炎病毒感染与原发性肝癌的关联性及危险因素分析. 实用癌症杂志,2017,32:1489-1493. [10] 黎莉,杨卫文,魏涛,等.乙型肝炎肝硬化并发原发性肝癌的危险因素Logistic分析.中国老年学杂志,2016,36:1653-1654. [11] 杨小敏,张娓,郑红斌.乙型肝炎肝硬化并发原发性肝癌的危险因素分析.中国现代医生,2013,51:54-58. [12] 陈萍, 李江, 苏菲, 等.乙型肝炎肝硬化并发原发性肝癌的危险因素评估. 安徽医科大学学报, 2012,,47: 1218-1221. [13] 赵雪珂,张权,陈莎莎,等.贵州省原发性肝癌危险因素的病例对照研究.重庆医学2014,43:1157-1160. [14] Schütte K, Tippelt B, Schulz C, et al.Malnutrition is a prognostic factor in patients with hepatocellular carcino(HCC).Clin Nutr,2015,34:1122-1127. [15] Tholey DM,Ahn J.Impact of hepatitis C virus infection on hepatocellular carcinoma.Gastroenterol Clin North Am,2015,44:761-773. [16] John JA,de M attos AA,da Silva Miozzo SA,et al. Survival and risk factors related to death in outpatients with cirrhosis treated in a clinic in Southern Brazil.Eur J Gastroenterol Hepatol,2015,27:1372-1377. [17] Inoue M, lwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan.Arch Intetn Med,2006,166:1871-1877. [18] Mendy ME, Welzel T, Lesi OA, et al. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in the ambia, U′est Africa.J Vira1 Hepat,2010,17:115-122. [19] Wang WH, Hullinger RL, Andrisani OM. Hepatitis B virusXprotein via the p38 MAPK pathway induces E2F1 release and ATR kinase activation mediating ps3 apoptosis.J Biol Chem, 2008,283:25455-25467. [20] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA,2006,295:65-73. [21] Jiang JH,Xiang BD,Li LQ,et al.Postoperative antiviral therapy with nucleoside analogs for patients with hepatitis B virus‐related hepatocellular carcinoma.Clin Res Hepatol Gastroenterol,2015,12:563-567. |